Tradewinds Capital Management LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 6.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,793 shares of the medical research company’s stock after selling 444 shares during the quarter. Tradewinds Capital Management LLC’s holdings in Amgen were worth $1,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. TrimTabs Asset Management LLC boosted its position in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC boosted its position in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after acquiring an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares during the last quarter. American Beacon Advisors Inc. bought a new position in shares of Amgen during the first quarter worth $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in shares of Amgen during the first quarter worth $121,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.19% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) Holdings Decreased by Tradewinds Capital Management LLC” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/21/amgen-inc-amgn-holdings-decreased-by-tradewinds-capital-management-llc.html.

Amgen Inc. (AMGN) opened at 182.96 on Friday. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10. The company has a 50-day moving average of $185.13 and a 200 day moving average of $171.60. The stock has a market cap of $133.50 billion, a P/E ratio of 16.66 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. Amgen’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 EPS. Analysts predict that Amgen Inc. will post $12.58 EPS for the current year.

A number of brokerages recently weighed in on AMGN. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group restated a “neutral” rating and set a $186.00 target price (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Thursday, September 7th. Morgan Stanley restated an “overweight” rating and set a $196.00 target price (up previously from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, UBS AG set a $180.00 target price on shares of Amgen and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $189.94.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.